FOLLOWING MYOCARDIAL INFARCTION (MI), various intrinsic pathological processes occur within the myocardium including oxidative stress-induced apoptosis, giving rise to stiffening of heart muscle, impaired cardiac function, and, ultimately, heart failure and death (3, 20, 22, 28, 37) . To date, treatment for MI with pharmaceutical agents has yet to be wholly successful, and due to the scarcity of organ donors, heart transplantation has yet to be a feasible option. Given this, stem cell therapy has gained considerable attention as an alternate method to repair or regenerate injured myocardium consequent to MI. Various investigations have demonstrated the ability of stem cells transplanted into the infarcted heart to engraft, differentiate into cardiac cell types, inhibit apoptosis and fibrosis, and improve cardiac function (4, 19, 36, 37) . However, previous reports have revealed transplanted stem cells into the infarcted myocardium demonstrate limited cardiac myocyte differentiation (9, 29) . Therefore, innovative stratagem aimed at enhancing cardiac myocyte differentiation from transplanted stem cells is monumental in the pursuit of optimizing stem cell transplantation for post-MI therapy.
Recently, microRNAs (miRs) have been identified as regulators of various physiological and pathological heart processes including cardiac development, differentiation, arrhythmias, hypertrophy, remodeling, and angiogenesis (5, 6, 10, 11, 30, 46, 55) . miRs are small, single-stranded, noncoding RNAs usually about 20 -24 nucleotides in length. They recognize the 3= untranslated region of their target mRNA and negatively regulate gene expression through translational repression, mRNA degradation, and deadenylation. Genetic manipulation imploring miRs for therapeutic applications has recently gained significant interest in the research community but remains in its infancy.
miR-1, a widely conserved, cardiac-and muscle-specific miR, has been identified in early heart development (23, 57, 58) . Previous studies have illustrated a relationship between miR-1 expression and myocardial differentiation through regulation of various cardiac markers including myosin heavy chain, myogenin, Hand2, MyoD, Mef2, Nkx2.5, cyclin-dependent kinase-9, and ␣-actin (8, 46, 58) . However, exploitation of miR-1 in embryonic stem (ES) cells for post-MI therapy has yet to be attempted. Based on previous assimilated knowledge regarding the effects of transplanted ES cells on infarcted myocardium and the role of miR-1 in cardiac myocyte differentiation, we hypothesize that overexpression of miR-1 in transplanted ES cells following MI will enhance cardiac myocyte differentiation from donor ES cells as well as attenuate MI-associated myocardial remodeling (23, 37, 44) . In the present study, our data demonstrate that hearts transplanted with miR-1-ES cells contain significantly more donor cellderived cardiac myocytes compared with respective controls. Additionally, we reveal that transplanted miR-1-ES cells significantly inhibit apoptosis through modulation of p-Akt and phosphatase and tensin homolog (PTEN) gene expression. Moreover, we show miR-1-ES cells attenuate oxidative stress in the injured myocardium. Finally, our data demonstrate enhanced cardiac function following transplantation of miR-1-ES cells post-MI. Our study establishes a strong foundation and rationale to pursue future research using microRNAs in the ongoing development of ES cell transplantation therapy for the treatment of MI.
MATERIALS AND METHODS
ES cell culture. Mouse CGR8 ES cells were passaged and maintained as reported previously (41) . In brief, cells were plated on 0.1% gelatin-coated tissue culture dishes in DMEM supplemented with 15% ES-qualified FBS, leukemia inhibitory factor, glutamine, nonessential amino acids, penicillin-streptomycin, ␤-mercaptoethanol, and sodium pyruvate.
miR-1-ES cell generation. Mouse pre-miR-1 oligonucleotides (5=-tgc tgT GGA ATG TAA AGA AGT ATG Tag ttt tgg cca ctg act gac TAC ATA CTT TTA CAT TCC A-3= and 5=-cct gTG GAA TGT AAA AGT ATG Tag tca gtc agt ggc caa aac TAC ATA CTT CTT TAC ATT CCA c-3=) were cloned into a pcDNA 6.2-GW/EmGFP expression vector (Invitrogen) containing the selectable marker blasticidin. The expression of miR-1 and green fluorescent protein (GFP) was driven by a cytomegalovirus promoter. CGR8 mouse ES cells were transfected with the pre-miR-1 expressing vectors using Lipofectamine 2000 (Invitrogen). Selection media containing 2 g/ml blasticidin (Invitrogen) was added 48 h post-transfection and was changed every 48 h. Two to three weeks thereafter, blasticidin resistant ES cell colonies (labeled miR-1-ES cells) were selected, expanded, and maintained in ES cell culture medium. For control cells, a subset of CGR8 ES cells was transfected with the mammalian expression vector pTurboFP635-C (Evrogen) encoding red fluorescent protein (RFP).
RNA extraction and real-time RT-PCR. Total RNA was extracted using RNA STAT-60 (Tel-Test). cDNA synthesis was performed with a Taqman MicroRNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer's protocol. Specific primers (Assay ID No. 002222; Applied Biosystems) and Taqman Universal PCR Master Mix (Applied Biosystems) were used for amplification and identification of miR-1. Real-time RT-PCR was performed using a CFX96 Real-Time System (Bio-Rad). The relative amount of miR-1 was normalized against U6 snRNA (Assay ID No. 001973; Applied Biosystems), and the fold change for miR-1 was calculated.
MI and ES cell transplantation. All mice were maintained and used following protocols approved by the University of Central Florida animal review board. C57BL/6 mice (8 -10 wk old; Jackson Laboratories) were divided into four study groups (n ϭ 8 animals/group): sham, MI ϩ cell culture media (MI ϩ CC), MI ϩ ES cells, and MI ϩ miR-1-ES cells. In brief, mice were anesthetized with 2.5% isoflurane, intubated, and ventilated using a rodent MiniVent (Harvard Apparatus). Following a left thoracotomy, the left anterior descending coronary artery was visualized, and a 7-0 ligature (CP Medical) was placed around the coronary artery. Following left anterior descending ligation, two separate intramyocardial injections of 10 l of media with or without 2.5 ϫ 10 4 cells were delivered into the peri-infarct region. The ribs, muscle, and skin were sutured, the lungs were expanded, and mice were extubated following weaning from the ventilator. Shamoperated animals received all surgical procedures as detailed above excluding the left anterior descending ligation. At day 14 following surgery, mice were euthanized with pentobarbital (80 mg/kg) followed by cervical dislocation. Hearts were removed, transversely cut, and fixed in formalin for further assessment. Prepared heart sections or heart homogenates from five to eight animals in each group (sham, MI ϩ CC, MI ϩ ES cells, and MI ϩ miR-1-ES cells) were analyzed for the data.
Immunohistochemistry. Heart sections were deparaffinized and immunohistochemically stained using primary antibodies against RFP (for ES cells; AB232; Evrogen) or GFP (for miR-1-ES cells; A3122; Invitrogen) and sarcomeric ␣-actin (A2172; Sigmaz). Heart sections were then incubated with Alexa 488-or Alexa 568-conjugated secondary antibodies (Invitrogen), respectively. Heart sections were washed and mounted with Anti-fade Vectashield mounting medium as mentioned above. Colocalization of ␣Ϫactin positive cells with GFP or RFP cells was counted as newly differentiated cells from transplanted donor cells in one to two sections from n ϭ 5-8 animals/ group. Sections were examined with Olympus and Leica TSC SP2 laser scanning confocal microscopes.
Histopathology. In brief, heart tissue was fixed in 4% buffered formalin, embedded in paraffin, and cut into 5 m serial sections. Embedded paraffin heart sections were placed onto Colorfrost Plus microscope slides (Fisher Scientific), deparaffinized, and rehydrated as reported previously (37) . Thereafter, heart sections were stained Mason's trichrome for teratoma formation and visualization of interstitial and vascular fibrosis. Using National Institutes of Health ImageJ software, interstitial fibrotic area was calculated by measuring the collagen-positive blue area (squared millimeters) within the infarct, peri-infarct, and noninfarct regions in one to two sections from five to eight hearts per group. Vascular fibrosis was calculated as the ratio of vascular fibrosis to vessel area ϫ 100% in one to two sections from five to eight hearts per group.
Terminal deoxynucleotidyl transferase dUTP-mediated nick-end labeling staining. Terminal deoxynucleotidyl transferase dUTP-mediated nick-end labeling (TUNEL) staining and analysis was performed as described previously by us and others (13, 18, 39, 40) . In brief, heart sections were deparaffinized and permeabilized with proteinase K (25 g/ml in 100 mM Tris·HCl). An in situ apoptotic cell death detection kit (TMR red; Roche Applied Biosystems) was used to detect host myocardium apoptotic nuclei. Heart sections were thereafter mounted with Anti-fade Vectashield mounting medium containing 4=,6-diamidino-2-phenylindole (DAPI; Vector Laboratories) for nuclear visualization. Sections were observed under Olympus and confocal microscopes. The percentage of total apoptotic nuclei was determined in the infarct and peri-infarct regions from n ϭ 5-8 animals/group. Percentage total apoptotic nuclei ϭ total number apoptotic nuclei/total number of DAPI ϫ 100%. Heart sections were also stained with an anti-sarcomeric-␣-actin antibody (A2172; Santa Cruz) to differentiate between apoptosis in cardiac myocytes and noncardiac myocytes. The percentage of cardiac myocyte apoptotic nuclei was calculated as follows: total number of red-stained apoptotic nuclei colocalized with sarcomeric ␣-actin/total number of bluestained nuclei with DAPI ϫ 100%.
Caspase-3 activity assay. Caspase-3 activity assay was performed using a caspase-3 colorimetric activity assay kit from BioVision (K106-200). Heart tissue was homogenized in radioimmunoprecipitation buffer containing protease inhibitors, phenylmethylsulfonyl fluoride, sodium orthovandate, and sodium fluoride. Homogenized heart tissue was centrifuged at 14,000 g for 5 min. Supernatant was removed and placed into fresh centrifuge tubes. Protein concentration was estimated using a Bio-Rad assay. Caspase-3 activity was performed per the manufacturer's instructions, and color reaction was measured in a microtiter plate reader (Bio-Rad) at 405 nm. Capsase-3 activity was plotted as arbitrary units. Data were collected from heart homogenates of n ϭ 6 -8 animals/group in duplicates.
Dihydroethidium staining. Superoxide generation within infarcted myocardium was determined using dihydroethidium (DHE) fluorescence staining. Following deparaffinization and hydration, heart sections were stained with 1 M/ml DHE for 25 min at room temperature. The fluorescent images were captured on an Olympus and confocal microscope. Using ImageJ, DHE fluorescence intensity was quantified in four to five randomly selected regions in the peri-infarct zone/section in seven to eight animals/group as reported previously (32) . The average corrected integrated density (after background correction) was calculated for each group, and DHE fluorescence intensity was plotted as arbitrary fluorescence units.
Akt activity assay. p-Akt was quantitated using a phospho-Akt1 (PAN) ELISA kit (X1844k; Exalpha Biological) as detailed in the provided protocol. In brief, hearts were homogenized and proteins were estimated as described above. Samples were added to the wells containing captured antibodies provided in the kit and incubated with detector antibody, horseradish peroxidase conjugated substrate, and a stop solution with washings in between each step. The developed color reaction was measured in a microtiter plate reader (Bio-Rad) at 450 nm. The values obtained from the ELISA were normalized to the total protein concentration for each sample as determined by the Bradford assay. Phospho-Akt graph was plotted as arbitrary units. Data were collected from heart homogenates of n ϭ 6 -8 animals/ group in duplicates.
PTEN ELISA. Phospho-PTEN (p-PTEN) was quantified using a Cell Signaling Technology Phospho-PTEN Sandwich ELISA kit (No. 7285) as detailed in the instruction manual. The developed reaction, proportional to the quantity of p-PTEN, was measured at 450 nm in a microtiter plate reader (Bio-Rad). ELISA results were corrected for the protein concentration of each tissue sample. p-PTEN data were collected from heart homogenates from n ϭ 6 -8 animals/group in duplicates and plotted as arbitrary units.
Western blot. Hearts were homogenized in radioimmunoprecipitation buffer, and protein concentration was estimated as aforementioned. Protein (100 g) was loaded and fractionated in a 10% polyacrylamide SDS gel and then transferred onto an Immun-Blot polyvinylidene difluoride membrane (Bio-Rad). The membrane was incubated with primary antibody (p-Akt (No. 4058), Akt (No. 4685), p-PTEN (No. 9554), and ␤-actin (No. 4967; Cell Signaling Technologies) for 1 h at room temperature or overnight at 4°C. The blots were then incubated with appropriate secondary anti-rabbit antibodies for 1 h at room temperature. Blots were visualized using a Pierce ECL Western Blotting Substrate (Thermo Scientific).
Matrix metalloproteinase-9 immunoassay. Matrix metalloproteinase (MMP)-9 concentration was determined by an enzyme-linked immunoassay (MMPT90; R&D Systems) as described by others and in the protocol provided with the kit (43, 50) . A color reaction, proportional to the amount of bound MMP-9, was measured in a microtiter plate reader (Bio-Rad) at 450 nm. Based on protein content of each sample, determined by Bradford assay, ELISA results were corrected. MMP-9 data were collected from heart homogenates from n ϭ 5-8 animals/group in duplicates and plotted as arbitrary units.
Echocardiography. Cardiac function was assessed 2 wk post-MI by transthoracic echocardiography in n ϭ 8 animals/group. Mice were anesthetized with 2% inhalant isoflurane using a nose cone system and placed on a temperature controlled heating pad. Echocardiography was performed using a Sonos 5500 Ultrasound system with a 15-6L hockey stick transducer. Left ventricular internal dimension-diastole, left ventricular internal dimension-systole, fractional shortening (left ventricular internal dimension-diastole Ϫ left ventricular internal dimension-systole/left ventricular internal dimension-diastole ϫ 100), and ejection fraction [left ventricular volume at end diastole Ϫ left ventricular volume at end systole/left ventricular volume at end diastole; left ventricular volume at end diastole and left ventricular volume at end systole were calculated using the Teichholz formula (48)] were assessed in short-axis view at the midpapillary muscle level.
Statistical analysis. All values presented are means Ϯ SE and were analyzed using SigmaStat3.5 software. Analysis of data was performed using the Students t-test, one-way ANOVA, and the Bonferroni test. Statistical significance was accepted for P Ͻ 0.05. Figure 1A is a schematic representation showing pre-miR-1 oligonucleotide sequence and vector design used to overexpress miR-1 in ES cells (miR-1-ES cells). Transfection efficiency using Lipofectamine was ϳ80% before use of selection media. Following selection, we were able to obtain ϳ100% miR-1 overexpressing ES cell line. Our miR-1-ES cells were then maintained in routine cell culture for 2 to 3 wk.
RESULTS

miR-1 overexpression in miR-1-ES cells.
Previous studies have suggested mature miR-1 expression within ES cells is undetectable or minimal (17, 46, 52). RT-PCR analysis was performed on our ES and miR-1-ES cells, and we report minimal mature miR-1 expression in our parental ES cells corroborating previous findings (Fig. 1, B ) (17, 46, 52) . It is noteworthy that we demonstrate a dramatic increase in miR-1 expression in miR-1-ES cells compared with parental ES cells (Fig. 1B) . Additionally, Fig. 1 , C (phase contrast) and D (green fluorescence), photomicrographs depict miR-1-ES cells expressing GFP.
miR-1 enhances cardiac myocyte differentiation. To assess whether miR-1 drives differentiation of transplanted ES cells into cardiac myocytes post-MI, heart sections were double immunolabeled for the cardiac myocyte marker ␣-actin and for GFP (miR-1-ES cells) or RFP (ES cells) to detect donor differentiated cells (Fig. 2, A-X) . Colocalization of ␣-actinpositive cells with GFP or RFP positive cells were identified and counted as newly differentiated cardiac myocytes from donor ES cells. Transplanted miR-1-ES cells prevent apoptosis in the infarcted heart. TUNEL staining was performed and representative photomicrographs are depicted in Fig. 3 , A-X. At day 14, there was a significant decrease in TUNEL-positive nuclei post-MI in miR-1 ES cell transplanted groups compared with ES cell and medium groups (means Ϯ SE; MI ϩ miR-1 ES cells: 0.55 Ϯ 0.06% vs. MI ϩ ES cells: 0.87 Ϯ 0.05% and MI ϩ CC: 1.45 Ϯ 0.14% TUNEL positive nuclei/total nuclei, respectively; P Ͻ 0.05; Fig. 3Y ). Next, apoptosis in cardiac myocytes post-MI was determined in heart sections by colabeling with sarcomeric ␣-actin (Fig. 4, A-D) . Our data reveal miR-1-ES cell transplanted hearts contained significantly fewer apoptotic cardiac myocyte nuclei compared with respective controls (P Ͻ 0.05; Fig. 4E ). To reinforce our TUNEL data, a caspase-3 activity assay was performed on heart homogenates from five to eight animals per group. A significant decrease in caspase-3 activity in hearts transplanted with miR-1-ES cells post-MI compared with hearts transplanted with ES cells or medium alone resulted (P Ͻ 0.05; Fig. 4F) .
Effects of miR-1-ES cells on Akt and PTEN expression in post-MI hearts.
Previous studies have identified direct and indirect mechanisms of apoptotic inhibition through activation of various cell survival cascades such as adenosine triphosphate-dependent tyrosine kinase (Akt) (41) . To evaluate expression levels of activated Akt in hearts transplanted with miR-1-ES cells, a phosho-Akt ELISA was performed (Fig. 5B) . We determined that hearts transplanted with miR-1-ES cells had significant activation of Akt compared with hearts transplanted with ES cells and cell culture medium (means Ϯ SE; MI ϩ miR-1-ES cells: 6.88 Ϯ 0.29, vs. MI ϩ ES cells: 5.45 Ϯ 0.14 and MI ϩ CC 3.86 Ϯ 0.59; P Ͻ 0.05; Fig.  5B ). Our ELISA data were confirmed using Western blot analyses as illustrated in Fig. 5A . To evaluate whether increased activation of Akt was attributable to inhibition of phosphoinositide-3-kinase (PI3K)/Akt signaling, levels of PTEN, an inhibitor of PI3K phosphorylation, were quantified (Fig. 5D ). Our ELISA data illustrate a significant reduction in PTEN concentration in hearts transplanted with miR-1-ES cells versus hearts transplanted with ES cells or cell culture medium (means Ϯ SE; MI ϩ miR-1-ES cells: 6.49 Ϯ 0.20, vs. MI ϩ ES cells: 8.12 Ϯ 0.44 and MI ϩ CC 10.08 Ϯ 0.47; P Ͻ 0.05; Fig.  5D ). Additionally, Western blotting was performed to validate our PTEN ELISA results (Fig. 5C) .
Transplanted miR-1-ES cells reduce MI-induced oxidative stress. To examine the consequence of miR-1-ES cells on MI-induced oxidative stress, we analyzed intracellular superoxide anion production in heart sections using DHE fluorescent staining at day 14 following MI or sham surgery (Fig. 6) . As shown in the representative photomicrographs (Fig. 6, A-X ) and summary data (Fig. 6Y) , DHE staining was significantly reduced in miR-1-ES cell transplanted hearts compared with ES cell and cell culture medium transplanted hearts (means Ϯ SE; MI ϩ miR-1-ES cells: 3.00 Ϯ 0.53, vs. MI ϩ ES cells: 6.08 Ϯ 0.43 and MI ϩ CC 11.37 Ϯ 1.20; P Ͻ 0.05; Fig. 6Y) .
Effects of miR-1-ES cells on interstitial and vascular fibrosis.
Heart sections were stained with Mason's trichrome and interstitial fibrosis (Fig. 7, A-H) was quantified. Quantitative analysis of trichrome-stained heart sections indicated, when compared with medium alone, both miR-1-ES cell and ES cell groups had a significant reduction in the amount of interstitial fibrosis (mean fibrotic area Ϯ SE; MI ϩ CC: 1.02 Ϯ 0.06 mm 2 vs. MI ϩ miR-1-ES cells: 0.36 Ϯ 0.04 mm 2 and MI ϩ ES cells: 0.49 Ϯ 0.03 mm 2 ; P Ͻ 0.05; Fig. 7Q ). However, there was no statistical significance in interstitial fibrosis between miR-1-ES cell and ES cell groups. Next, quantitative analysis of vascular fibrosis (Fig. 7, I -P) revealed miR-1-ES cell and ES cell transplanted hearts had a significant reduction in the amount of vascular fibrosis compared with hearts transplanted with cell culture medium (P Ͻ 0.001; Fig. 7R ). Again, as with interstitial fibrosis, statistical significance was not reached between miR-1-ES cell and ES cell groups for vascular fibrosis.
Furthermore, MMP-9, a mediator of extracellular matrix degradation and indicator of myocardial fibrosis post-MI, was quantified. miR-1-ES cell and ES cell transplanted hearts demonstrated significantly reduced MMP-9 concentration compared with control hearts (P Ͻ 0.01; Fig. 7S ). However, as observed with interstitial and vascular fibrosis, there was no significant difference between miR-1-ES cell and ES cell groups.
No teratoma formation in miR-1-ES cell transplanted hearts. ES cells have the capacity to differentiate into all derivatives of ectoderm, endoderm, and mesoderm, presenting the risk of teratoma formation at the injection site. Masson's trichrome-stained heart sections demonstrated no teratoma formation in any of the miR-1-ES cell or ES cell transplanted hearts (Fig. 8) .
Overexpression of miR-1 improves cardiac function post-MI.
To evaluate the functional consequences of transplantation of miR-1-ES cells in infarcted myocardium, echocardiography was performed. Primary raw data obtained are included in Fig. 9A . Quantitative analyses showed mice receiving ES cell transplantation following MI had significantly improved fractional shortening compared with medium alone (P Ͻ 0.001; Fig. 9B ). Additionally, mice transplanted with miR-1-ES cells post-MI had significantly increased fractional shortening when compared with both ES cell and medium control groups (means Ϯ SE; MI ϩ miR-1-ES cells: 43.88 Ϯ 0.33%, vs. MI ϩ ES cells: 40.53 Ϯ 0.74% and MI ϩ CC 32.33% Ϯ 0.97%; P Ͻ 0.01; Fig. 9B ). Furthermore, miR-1-ES cell transplanted mice post-MI also had significantly improved ejection fraction when compared with mice transplanted with ES cells or medium post-MI (P Ͻ 0.05; Fig. 9C ).
DISCUSSION
The efficacy of cardiac myocyte differentiation from transplanted ES cells remains a major challenge to post-MI cell therapy. Numerous attempts have been made to enhance and drive cardiac myocyte differentiation from stem cells using various growth factors including bone morphogenetic protein-2, transforming growth factor ␤ 2 , VEGF, IGF-1 and -2, activin-A, FGF-2 and -4, IL-6, and EGF (2, 42, 53, 56) . Despite these efforts, the observed donor cell differentiation into cardiac myocytes remains insufficient to regenerate the infarcted heart (9, 29) . Recently, miRs have been implicated in the differentiation of a myriad of cells types including epidermal cells, adipocytes, osteoblasts, neuronal cells, and cardiac muscle (12, 23, 25, 26, 54) . In the present study, we transfected ES cells with miR-1, a procardiac microRNA and transplanted them into the peri-infarcted myocardium as we and others have shown that transplantation of various stem cell populations do not engraft and differentiate in sham and noninfarcted regions of the heart (15, 27, 36) . Following transplantation, we evaluated the effects of miR-1-ES cells on cardiac myocyte differentiation, apoptosis, fibrosis, oxidative stress, and cardiac function.
Our data for the first time suggest miR-1, when transfected in ES cells, following transplantation into the infarcted myocardium, significantly increases the amount of donor cellderived differentiated cardiac myocytes compared with untransfected ES cells. Our data corroborate with reports that miR-1 participates in early cardiac development in Drosophila and mice as well as enhance cardiac myocyte differentiation in the cell culture system (23, 57, 58) . Although several miR-1 targets have been identified in the developing heart and cell culture system including histone deacetylase 4, heart and neural crest derivatives-expressed protein 2 and cyclin-dependent kinase-9 (6, 46, 49) , the mechanisms by which miR-1 transfected ES cells promote cardiac differentiation in the infarcted heart remain unknown.
Endothelial and vascular smooth muscle cell death plays a significant role in the loss of vascularization, which also contributes to cardiac dysfunction (39) . In this regard, neovascularization remains an active area of research. Previous studies have described the vascular potential of ES cells demonstrating their contribution to the activation of c-kit and Flk-1 ϩ progenitor cells and their differentiation into endothelial and vascular smooth muscle cells (36, 39) . However, whether transplanted miR-1-ES cells enhance activation of vascular progenitor cells and differentiation into vascular cell types in the infarcted myocardium is unknown and warrants future research.
Next, it was imperative to investigate whether transplanted miR-1-ES cells promote additional repair mechanisms via inhibition of apoptosis and fibrosis in the infarcted myocardium. In the current study, we report that transplanted miR-1-ES cells significantly reduce endogenous cardiac myocyte apoptotic cell death in the infarcted heart compared with untransfected ES cells. Our data are the first report demonstrating inhibition of cardiac myocyte cell death post-MI with transfected miR-1-ES cells. In contrast, several published reports have suggested that miR-1 is proapoptotic in cardiac myocytes following MI (34, 47) . However, the experimental design reported in the current study is completely distinct compared with the studies in which miR-1 is reported to be apoptotic, which may explain the discrepancies between the varying results (34, 47) . Moreover, we are not the first group to report conflicting apoptotic data relative to miRs in various cell lines. In fact, Wang (51) recently concluded upon reviewing published data on miR-21 that a single miR has the potential to be apoptotic, antiapoptotic, or neutral, depending on the cell line in which it is being expressed.
Apart from our current findings suggesting miR-1-ES cells are antiapoptotic in the host injured myocardium, we did not quantify the amount of apoptosis of transplanted cells that had either engrafted or differentiated into cardiac myocytes. However, it would be fascinating for future studies to evaluate whether engrafted and differentiated transplanted miR-1-ES cells also demonstrate inhibited apoptosis compared with untransfected ES cells. Additionally, to determine proliferation of the transplanted miR-1-ES cells in the infarcted myocardium at various time intervals is of particular interest. Therefore, future studies in this direction are warranted.
In an attempt to elucidate mechanisms by which miR-1-ES cells inhibit host myocardium apoptosis post-MI, we investigated the connection between miR-1 and the PI3K/ Akt pathway. The PI3K/Akt pathway is a well-documented signaling cascade, which controls regulation of various cellular processes including cell growth, proliferation, and survival. Additionally, previous studies have demonstrated Akt to be cardioprotective and antiapoptotic post-MI (14) . To this end, we assessed the levels of activated Akt by ELISA and Western blotting and were able to elucidate a positive correlation between Akt activation and apoptosis inhibition in miR-1-ES cell transplanted hearts. Specifically, we noted that as apoptosis was significantly decreased in miR-1-ES cell transplanted hearts, levels of p-Akt were significantly increased compared with ES cell and cell culture medium transplanted hearts. Although we were able to make this distinction, Akt mRNA is not a predicted target of miR-1. To that end, we turned our investigation to upstream components of the Akt pathway.
PTEN, an inhibitor of PI3K phosphorylation, blocks the subsequent activation and phosphorylation of Akt. Additionally, previous studies have indicated an increase in PTEN activity following ischemic events, suggesting its role in myocardial injury (21). Therefore, we could circumvent that downregulation of PTEN in the heart would result in increased PI3K/Akt signaling leading to restrained cardiac myocyte apoptosis and inhibited maladaptive myocardial remodeling. Our ELISA data, confirmed by Western blot, was in corroboration with this line of thought since PTEN levels were significantly decreased in hearts transplanted with miR-1-ES cells compared with ES cell or cell culture medium transplanted hearts. Although miR-1 is not predicted to target PTEN directly, negative regulation of PTEN activators may explain the increase in Akt activity and decrease in PTEN observed within this study (33) . In fact, a recent published paper demonstrated a correlation between miR-101 and membrane-associated guanylate kinase, WW and PDZ domain-containing 2 (MAGI-2), a protein required for PTEN stabilization, leading to Akt activation and diminished PTEN activity as we suggest within the present study (33) . However, because predicted targets of miR-1 span a myriad of mRNAs with a host of biological activities, determination of whether miR-1 regulates these targets is beyond the scope of this study and requires further investigation.
Oxidative stress is a key mediator of myocardial apoptosis following MI (1, 38, 41) . Oxidative stress-induced cardiac myocyte apoptosis involves the activation of two independent pathways (Bcl-2 family activated mitochondrial intrinsic pathway and Fas ligand or TNF-␣ extrinsic pathway) through generated reactive oxygen species including superoxide (O 2 ·Ϫ ), hydroxyl (
• OH), hydrogen peroxide (H 2 O 2 ), and peroxynitrite (ONOO Ϫ ) (16) . Because miR-1 is not limited to single target regulation, we examined whether miR-1-ES cells also confer direct antiapoptotic protective effects on infarcted myocardium through reactive oxygen species attenuation. Our data demonstrate that although MI induced the generation of superoxide in the myocardium, transplanted miR-1-ES cells blunted superoxide production. Our study suggests that miR-1-ES cells may prevent apoptosis not only through activation of the cellsurvival PI3K/Akt pathway, but also through regulation of reactive oxygen species generation.
In other respects, not only does adverse cardiac remodeling involve apoptosis but also the formation of fibrosis to rescue the architecture of the infarcted myocardium. Fibrosis formation involves the activation of MMPs, degradation of the extracellular matrix, and increased collagen deposition. Previous studies have shown that stem cells following transplantation post-MI inhibit fibrosis formation (35, 37) . Although a trend of attenuated interstitial and vascular fibrosis was reported, our data show that hearts transplanted with miR-1-ES cells post-MI demonstrate no significant additional decrease in fibrosis compared with untransfected ES cells. MMP-9, a well-established mediator of ventricular remodeling, was also assessed to establish a relationship between miR-1-ES cells and blunted fibrosis. However, MMP-9 expression was not significantly diminished in miR- 1-ES cell transplanted hearts relative to ES cell transplanted hearts. Our data indicate that although not significant, our miR-1-ES cells were able to parallel the antifibrotic effects of ES cells post-MI.
In the current study, we report that transplantation of ES or miR-1-ES cells in the infarcted myocardium did not give rise to teratoma formation. Our reported findings are in agreement with various published reports indicating no teratoma formation following transplantation of 30,000 (37), 50,000 (31) , and 300,000 (15) undifferentiated ES cells. Numerous previous published reports have provided evidences of tumor formation containing derivatives from all three germ layers following transplantation of undifferentiated ES cells into the myocardium (7, 31, 45) . However, these studies in which teratoma formation occurred reported transplanting anywhere from 100,000 to more than 1 million ES cells (7, 45) . Moreover, whether miR-1 overexpressing ES cells will or will not induce teratoma formation following transplantation in the infarcted heart in a dose-dependent manner remains to be established. Overall, our data as well as that of others suggest that teratoma versus no-teratoma formation in the infarcted heart is regulated by the number of ES cells transplanted (24, 31) .
Finally, we needed to determine whether transplantation of miR-1-ES cells contribute to improved cardiac function following MI as the success of ES cell transplantation for post-MI therapy ultimately is defined by the improvement in cardiac contractility and output. In the present study, we have demonstrated that 2 wk following MI, mice transplanted with miR-1-ES cells had significantly increased fractional shortening and ejection fraction compared with mice transplanted with ES cells. Conceivably, enhanced cardiac myocyte differentiation from transplanted miR-1-ES cells within the infarcted myocardium resulting in attenuated adverse remodeling contributed to improved overall cardiac function.
In conclusion, we report that 1) miR-1 promotes ES cell differentiation into cardiac myocytes in the infarcted heart, 2) miR-1-ES cells inhibit cardiac myocyte apoptosis, 3) inhibited apoptosis mediated by miR-1-ES cells involves the PI3K/PTEN/Akt pathway, 4) inhibited apoptosis is also associated with attenuated oxidative stress in miR-1-ES cell transplanted hearts, 5) miR-1-ES cells inhibit interstitial and vascular fibrosis relative to control MI, and 6) transplanted miR-1-ES cells post-MI improve cardiac function. 
